Organization
Novo Nordisk Canada Inc.
- Meetings this Parliament
- 41
- With MPs
- 20
- Since Nov 2021
- 102
- Active registrations
- 1
Most recent reported meeting: Sep 25, 2026.
Lobbying by Novo Nordisk Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (organization) In effect since Sep 18, 2026
Filed by Iain Graham, General Manager
Lobbyists
-
Gabrielle Berard · Director, External Affairs
Former designated public office holder
Formerly Director of Parliamentary Affairs, Senate of Canada, Parliament of Canada (2017–2018)
Formerly Policy Advisor, Office of the Minister of Finance, Finance Canada (2011–2014)
- Luka Stevanovic · External Affairs Associate Director
- Michael Tucker · Patient Access Manager, Atlantic
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Canada Foundation for Innovation, Canadian Heritage (PCH), Canadian Human Rights Tribunal (CHRT), Canadian Institutes of Health Research (CIHR), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), National Research Council (NRC), Parks Canada (PC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (9)Hide details
- Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
- Advocating in support of Bill S-201, An Act respecting a national framework on sickle cell disease.
- Free trade agreements as they relate to the biopharmaceutical industry.
- Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
- Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
- Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
- Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
- Advocate for the implementation of a federal diabetes and obesity strategy.
- Advocate for the establishment of public-private partnerships to support chronic disease prevention.
Registration 963537-360616-26. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Vince Lamanna (55), Béatrice Clerc (26), Iain Graham (21).
-
Reported by Vince Lamanna · In-house (organization)
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians. Read more
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Vince Lamanna · In-house (organization)
- Parm Bains · Member of Parliament
Advocate for the establishment of public-private partnerships to support chronic disease prevention. Read more
Advocate for the implementation of a federal diabetes and obesity strategy.
-
Reported by Vince Lamanna · In-house (organization)
- Ali Ehsassi · Member of Parliament
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Vince Lamanna · In-house (organization)
- Matt Strauss · Member of Parliament
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages. Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Free trade agreements as they relate to the biopharmaceutical industry.
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
-
Reported by Vince Lamanna · In-house (organization)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
-
Reported by Vince Lamanna · In-house (organization)
- Daryl Fridhandler · Senator, Senate of Canada
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
-
Reported by Vince Lamanna · In-house (organization)
- Peter Fragiskatos · Member of Parliament
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians. Read more
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Vince Lamanna · In-house (organization)
- Sonia Sidhu · Member of Parliament
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians. Read more
Advocate for the implementation of a federal diabetes and obesity strategy.
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
-
Reported by Vince Lamanna · In-house (organization)
- Dan Mazier · Member of Parliament
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians. Read more
Advocate for the implementation of a federal diabetes and obesity strategy.
-
Reported by Vince Lamanna · In-house (organization)
- Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians. Read more
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
-
Reported by Vince Lamanna · In-house (organization)
- Manuela Tomic · Senior Policy, Innovation, Science and Economic Development Canada (ISED)
- Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Support the establishment of a life sciences strategy in Canada
-
Reported by Vince Lamanna · In-house (organization)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages. Read more
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Vince Lamanna · In-house (organization)
- Karim Bardeesy · Parliamentary Secretary to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages. Read more
Support the establishment of a life sciences strategy in Canada
-
Reported by Vince Lamanna · In-house (organization)
- Matthew Hall · Senior Policy Advisor, Prime Minister's Office (PMO)
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Vince Lamanna · In-house (organization)
- Yash Nanda · Policy Advisor, Prime Minister's Office (PMO)
Advocate for the implementation of a federal diabetes and obesity strategy. Read more
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Vince Lamanna · In-house (organization)
- Sandenga Yeba · Director of Policy, Health Canada (HC)
- Shahad Khallidi · Deputy Director of Policy, Health Canada (HC)
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Vince Lamanna · In-house (organization)
- Lesley Sherban · Chief of Staff, Global Affairs Canada (GAC)
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Vince Lamanna · In-house (organization)
- Tania Belisle-Leclerc · Director of Policy, Global Affairs Canada (GAC)
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Vince Lamanna · In-house (organization)
- Eshan Naik · Director of Policy, Health Canada (HC)
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Vince Lamanna · In-house (organization)
- Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Vince Lamanna · In-house (organization)
- Scott Tannas · Senator, Senate of Canada
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages. Read more
-
Reported by Vince Lamanna · In-house (organization)
- Ya'ara Saks · Minister of Mental Health and Addictions, Associate Minister of Health, Health Canada (HC)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
Health
-
Reported by Vince Lamanna · In-house (organization)
- Shuvaloy Majumdar · Member of Parliament
Health
-
Reported by Vince Lamanna · In-house (organization)
- Corey Tochor · Member of Parliament
Health
-
Reported by Vince Lamanna · In-house (organization)
- Ritu Bannerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthResearch and Development
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.